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ABSTRACT
Current treatments for prostate cancer (PCa) are marred with high relapse frequency and
development of progressively aggressive cancers; developing new treatment options for PCa
remains crucial. In this project, a series of synthetic compounds based on natural products will
be screened to identify inhibitors for Aurora-A kinase (Aur-A). Aur-A facilitates centrosome
separation and bipolar spindle formation during mitosis. Aur-A is overexpressed in metastatic
PCa cells, and is a good candidate for targeted therapies. Compound libraries are designed using
natural compounds that contain simple structural elements as starting points for developing drug
like libraries.

High-throughput screening of these libraries will be used to identify potent

antimitotic agents that selectively affect cancer cells but not normal cells. A combination of in
vitro protein assays – quantifying protein activity – cell-based assays – measuring cell growth
and proliferation – and cell-reporter assays – to determine which metabolic pathway the
compound affects – were used to identify potential inhibitors. Through these methods, we have
identified several compounds, with special consideration to thiazole piperazine compounds, to
successfully inhibit proliferation of metastatic PCa cells.
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INTRODUCTION
Prostate cancer (PCa) remains one of the most pervasive and deleterious diseases known
to affect mankind, both with its widespread occurrence in all men and its extreme persistence
against treatment. According to the American Cancer Society estimates, 1 in 7 men will become
diagnosed with PCa at some point in their lives and 1 in 39 will perish from the disease. Prostate
cancer affects all races, with the highest rates of incidence occurring in Non-Hispanic Black
men. Combined with the highest incidence rate of all cancers, 131.5 per 100,00 citizens in 2015,
searching for new viable treatment options that lower the rate of relapse frequency and cause less
discomfort for the patient is a crucial task for the medical community.
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BACKGROUND
Androgen Receptor
The androgen receptor normally binds two primary ligands, the lipophilic hormone
testosterone and the testosterone derivative dihydrotestosterone. Androgen signaling is vital for
the regulation of the growth and development of the male sexual phenotype, which includes
reproductive organs and primary sex characteristics, secondary sex characteristics and proper
psychological development throughout a man’s life. The androgen receptor is constitutively
expressed as a cytosolic, inactive prostatic 110kDa class I steroid receptor protein bound to
various stabilizing proteins such as hsp90, hsp70, and hsp56 (Roy et.al, 2001). Androgens are
capable of freely diffusing across the phospholipid bilayer of a cell and may free bind the ligandbinding domain of the androgen receptor, causing conformational change that activates the
receptor and ultimately leads it to become translocated into the nucleus.
While in the nucleus, the androgen receptor binds to specific androgen response elements
(AREs) in genomic DNA to, along with transcriptional enhancers that are recruited, induce
transcription of genes that are subsequently under androgen control. For PCa, this androgendependency causes an overexpression of particular genes including PSA, which at high-serum
concentrations is indicative of PCa (Riegman et al., 1991). And while there are so many diverse
metabolic pathways and cellular processes in which the androgen receptor is involved, it remains
clear that androgen receptor signaling in PCa leads to the survival of cancerous prostatic cells.
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Clinical treatment of Prostate Cancer
For those with localized prostatic cancer, common treatments include radiation therapy
and/or radical prostatectomy along with active surveillance. However patients with highly
aggressive metastatic PCa are treated with androgen deprivation therapy, which uses a
combination of drugs to simultaneously block androgen receptor function and deplete androgen
levels for cancerous cells. Non-steroidal anti-androgen drugs such as flutamide, nilutamide, and
bicalutamide are commonly used to antagonistically block androgen receptor activity in the
prostate (Sharifi et al., 2010).. Despite a transient period of improvement, however, after a about
18 to 24 months, relapse occurs: PSA levels begin to rise again, tumor progression returns, and
while the cancerous symptoms become more pronounced, the cancer itself becomes more
aggressively metastatic and more difficult to treat (Chen et al., 2009). This is a result of the fact
that the cancer becomes resistant to anti-androgen and androgen deprivation therapies.
Targeting the Mitotic Process in Cancer Cells
In this study, we suggest a different mechanism by which we attack the cancer: attack the
mitotic division process itself. With this method, we hope to attack PCa by taking advantage of
its gross proliferative capabilities and halting the mitotic process altogether. Aur-A, a
serine/threonine kinase, is overexpressed in a variety of adenocarcinomas including, but not
limited to, breast, skin and prostate metastasis (Das et al., 2010). Therefore, recent research has
been dedicated to identifying potential Aur-A inhibitors to be used singly or in combination with
epidermal growth factor receptor (EGFR) inhibitors. For example, a known Aur-A inhibitor,
MLN 8237, has been shown success in clinical trials and is used in this project as a positive
inhibitor control.
3

As for the mechanism of Aur-A kinase, it’s involved in centrosome separation and
bipolar spindle formation during mitosis. It physically interacts with LIMK1 and activates it
through phosphorylation at Serine307. Serine307 is located in a gap region that contains a PDZ
domain, for anchoring to cytoskeletal components, and a kinase domain. Aur-A also acts as a
substrate of LIMK1 and both enzymes colocalize during spindle formation. Both LIMK1 and
Aur-A are overexpressed in metastatic PCa cells, and are good candidates for targeted therapies
(Ritchey, Roumanos, & Chakrabarti, 2012). Specifically, Aur-A has recently been shown to
affect spindle formation by inducing changes in the actin-cytoskeleton. It regulates actincytoskeleton reorganization by phosphorylating cofilin at multiple sites, thereby inhibiting its
actin depolymerization function. Using MLN 8237 to inhibit Aur-A results in defects in spindle
morphology and multipolarity. Inhibition of Aur-A kinase, therefore, induces a delay in the
mitotic progression of the cell cycle at the G2/M checkpoint, inducing apoptotic mechanisms
(Ritchey & Chakrabarti, 2014).
Moreover, Aur-A has been shown to promote tumor proliferation and cell reprogramming
through activation of epithelial-mesenchymal transition (EMT). Aur-A has been shown to
accomplish two non-metastatic roles in cancerous cells: promote tumor progression through
EMT by stabilizing the Snail transcription factor; and showing a functional association with
SMAD5 and SOX2-related EMT. With this information, we hope to attack Aur-A to affect its
modulation of oncogenic pathways involved in centrosome separation, mitotic spindle formation,
cell migration, chemoresistance, tumor initation ability, and onset of distant metastases
(D’Assoro, Haddad & Galanis, 2015).
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OBJECTIVE OF THE STUDY
This study was focused on drug screening millions of small molecular synthetic
compounds against Aur-A to identify potential anti-proliferative cancer reagents for future drug
study. Several major aspects of the study should be noted. We initially screened the effect of
compounds on inhibition of Aur-A through the use of the Kinase Glo Assay. We identified
“potential hits” as compounds that showed at least 60% inhibition of Aur-A activity at a
concentration of 10μg/mL or 10μM. We determined the IC50 of potential hits by performing the
Kinase Glo Assay on varying dilutions of compounds and using nonlinear regression analysis to
produce a dose-response curve. We screened all compounds for cytotoxicity against the PC-3
(human prostate cancer) cell line using the MTS Assay to identify compounds exhibiting at least
50% cytotoxicity effects and determine the LD50 of the potential hits. We determined the
hormone receptor pathway the compounds targeted the most by using a Cell-Based Cignal
Reporter Assay as well as identified potential new targets of highly aggressive metastatic cancer.
In combination, this enabled us to find the most favorable active compounds for future
optimization and drug screening, ultimately isolating anticancer scaffolds for development as
cancer therapy drugs that are effective in the nanomolar range.
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MATERIALS AND METHODS
Experimental Plan
The experimental plan was comprised of two phases:
•

M1 – Data acquisition, through Kinase Glo, MTS, and cell-reporter assays

•

M2 – Data analysis, and identifying potential anti-proliferative cancer agents

M1. Kinase Glo Assay
Principle
by enzymatic activity. For our study, by incubating Aur-A along with its substrate cofilin
and a determined amount of ATP, Aur-A will phosphorylate a given amount of cofilin, depended
on its activity, and residual ATP will remain. The Kinase Glo Assay introduces the luciferase
enzyme, which utilizes ATP to catalyze the oxidation of Beetle Luciferin to oxyluciferin whilst
emitting photons of light in the process. We can quantify this luminescence using a luminometer
and determine how much activity Aur-A had alongside a treatment with the compounds.
Reagents
Elutions of 1μM and 10μM ATP were a gift from Lisa Ritchey. Torrey Pines Institute
(TPI) supplied us with libraries of compounds that were synthesized from natural compounds by
using teabag peptide synthesis. Libraries were separated by similar molecular backbones in the
initial scaffold ranking plate and separated by similar backbones and unique reactive groups for
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the secondary positional scanning plates. Asinex Corporation supplied us with small molecular
individual compounds synthesized from natural compounds. 10X Kinase assay buffer was made
with 50 mM MOPS pH 7.2, 25 mM β-glycerophosphate, 10 mM EGTA, 4 mM EDTA, 50 mM
MgCl2, and 0.5 mM DTT.
Protein Purification
The coding sequence of human Aur-A was cloned into pET30Ek/LIC vector (Novagen).
Proteins were expressed by transforming BL21-CodonPlus (DE3) RIPL cells using our published
method (Ellis, Davila & Chakrabarti, 2003). Transformed cells were induced with 1 mM IPTG
at 20°C overnight. Proteins were purified using a Talon Beads cobalt affinity column (Clontech)
and eluted using an Imidazole concentration gradient. Proteins eluted at around 35μM Imidazole
concentration. His-cofilin was purified using the same method. Elution fractions are pictured in
the figure below for Aur-A (Fig. 1) and for Cofilin (Fig. 2).
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Figure 1) SDS-PAGE of Aur-A Fractions. Fractions 4-11 were collected and purified using
a Pierce Concentrator, yielding 3mL of 2mg/mL Aur-A

Figure 2) SDS-PAGE of Cofilin Fractions. Fractions 3-9 were collected and purified using
a Pierce Concentrator, yielding 2mL of 4.6mg/mL of Cofilin substrate.
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Experimental design
We optimized this assay so that each 10μL reaction well would contain the following:
10μM ATP, 1x Kinase buffer, 1μg Aur-A, 1μg cofilin, and a variable concentration of the
treatment. Negative controls had all reagents except Aur-A, vehicle controls were treated with
2.5% DMF, positive controls were treated with dH2O, and the MLN controls were treated with
1μM MLN 8237. All reagents were prepared on ice to preserve kinase activity and compound
integrity. The reaction mix was allowed to incubate for 30 minutes at room temperature, after
which we added the Kinase Glo Reagent and incubated for 10 minutes. The luminometer was
then used to quantify luminescence in each well. Unless specified, all Kinase Glo assays were
completed in 384 – well white bottom plates, and all treatments were performed in duplicate.
Potential hits – defined as compounds or compound libraries that showed greater than 60%
kinase activity inhibition – were then used to experimentally determine their IC50. We used
10μM, 5μM, 2.5μM and 1μM concentrations. Percent inhibition was calculated and graphed.
We calculated the IC50 from the logarithmic line of best fit from that graph.
M1 – MTS Assay
Principle
The MTS Assay is a cell viability assay that uses a novel compound [3-(4,5dimethylthiazole-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, MTS]
that is bioreduced by viable cells to form a tissue culture medium soluble formazan product
using phenazine ethosulfate (PMS) as an electron-coupling reagent. Formazan is a colored
9

product that can be quantified by measuring the absorbance at 490nm and is directly proportional
to the number of living cells in the medium. We used this assay to determine the cytotoxic
effects of the compounds on the PC-3 cell line.
PC-3 Cell Line
PC-3 cells were established in 1979 from a bone metastasis of a stage IV prostate cancer
of a 62 year old Caucasian male. PC-3 cells are highly metastatic and are androgen,
glucocorticoid, EGF and FGF insensitive (Kaighn et al., 1979)
Experimental Design
Richard Ottman maintained cell culture of PC-3 cells before drug treatment. 750 PC-3
cells were seeded into each well of a 384-well Grenier clear bottom plate and allowed to grow
for 24 hours in 25μL of PC-3 media. We changed the media and treated the cells using either
10μM or 10μg/mL of Asinex compounds and incubated for 48 hours. 20% of MTS volume was
the amount of PMS we added to the MTS reagent. We added the MTS reagent to the cells and
incubated for 4 hours before we read the absorbance at 490nm and 620nm. Live controls were
treated with normal PC-3 media, and vehicle controls were treated with 2.5% DMF. Dead
controls we did not treat; 15 minutes before adding the MTS/PMS reagent, we added 20%
Tween to the Dead controls. All treatments were performed in quadruplicate. Potential hits –
defined as compounds or compound libraries that showed greater than 50% cell cytotoxicity–
were then used to experimentally determine their LD50. We used 20μM, 10μM, 5μM, 2.5μM and
1μM concentrations. Percent inhibition was calculated and graphed. We calculated the LD50
from the logarithmic line of best fit from that graph.
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M1 – Cignal Finder Cell Based Reporter Assay
Principle
The Cignal Finder Cell Based Reporter Assay (Cell Reporter Assay) is a cell-based
reporter assay that quantifies the activity of key cell signaling pathways via their target
transcription factors. We used certain cell lines that express a specific receptor and transfected
the cells with a Firefly luciferase construct that is responsive to that receptor and a Renilla
luciferase that is constitutively expressed. The Firefly luciferase reporter gene is under
regulation of a minimal (m)CMV promoter – a strong synthetic promoter for mammalian cells –
and tandem repeats of a transcriptional element downstream of the specified receptor. This
allows accurate quantification of small synthetic compound activity on certain cell signaling
pathways by comparing the Firefly luminescence to a constitutively expressed Renilla
luminescence. In this study, a decrease in Firefly/Renilla ratio suggests an inhibition of the
specified receptor’s activity.
Cell Lines Used and Their Receptors
HepG2 is a human cell line from a well-differentiated hepatocellular carcinoma and was
used for their HNF4 and Liver X receptors. MCF-7 is a human breast cancer cell line used for its
progesterone receptors. LNCaP is a human androgen-sensitive prostate adenocarcinoma cell line
used for its androgen receptors. HeLa is an immortal human cervical cancer cell line used for its
glucocorticoid and PPARγ receptors.
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Cell Line

Description

Receptor(s)

HeLa

Immortal human cervical
cancer cell line

Glucocorticoid Receptor

Human well-differentiated
hepatocellular carcinoma

HNF4

LNCaP

Metastatic prostate
adenocarcinoma

Androgen Receptor

MCF-7

Metastatic breast carcinoma

Progesterone Receptor

HepG2

Table 1) Cell Lines and their Receptors
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PPARγ

LXR

Experimental Design
Richard Ottman handled all tissue culturing and maintenance. All cell lines were allowed
to grow for 48 hours, and we proceeded to split and seed 500 cells into 50μL of media in 96-well
clear bottom plates. After 8 hours of growth, we transfected the cells with 100ng of Cignal
Reporter, negative control, or positive control DNA depending on the treatment. We changed
the media 15 hours later, and treated the cells using 10μg/mL of the TPI compound libraries 20
hours after transfection. After 19 hours of incubation, we read the Firefly and Renilla
luminescence values. Positive control DNA includes a constitutively expressing Firefly
luciferase reporter gene and a constitutively expressing Renilla luciferase reporter gene.
Negative control DNA includes a non-inducible Firefly luciferase reporter gene and a
constitutively expressing Renilla luciferase reporter gene. Cignal reporter DNA includes a
receptor sensitive Firefly luciferase construct that is under regulation of a minimal CMV
promoter and tandem repeats of a transcriptional element, specific to one of the receptor types
outlined above, downstream of the specified reporter. Vehicle controls were treated with 2.5%
DMF. All treatments were performed in single replicate.
M2 – Data Analysis and Identification of Potential Antiproliferative Agents
Kinase Glo Assay
For this assay, we quantified kinase activity by first taking the average of the duplicates
of each treatment. We then calculated percent inhibition using the following equations below in
succession:
13

Compound or compound libraries that showed more than 60% inhibition were labeled as
“potential” hits.
MTS Assay
For this assay, we quantified cell viability by first taking the average of the
quadruplicates of each treatment. We then subtracted the average Dead Control from every
treatment to subtract the background absorbance. Cell viability, then, was calculated using the
following equation below:

“Potential hits” were compounds that inhibited at least 50% cell viability.
Cignal Finder Cell Based Reporter Assay
For this assay, we quantified receptor signaling activity by taking the ratio of Firefly
Luminescence and Renilla Luminescence. We then normalized all treatments to the average
Vehicle Control Ratio by using the following equation:
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We then found the percent difference from the average vehicle ratios using the following
equation:

“Potential hits” were identified as compound libraries that showed more than 60% cell
signaling inhibition in less than three receptor signaling pathway.
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RESULTS
TPI Compound Library Screening
Kinase Glo Assays
In the first high-throughput screening of the scaffold ranking plate from TPI, we found
two compound libraries to show greater than 60% kinase activity inhibition: Library 2057 and
Library 2165 (Fig. 6). After the initial scaffold ranking plate screening, where we identified two
compound libraries – 2057 and 2165 – that significantly inhibited Aur-A by at least 60%, we
continued onto the secondary positional ranking plate. This secondary positional ranking plate
separated compound library 2057 into 80 different libraries with similar molecular backbones
and fixed certain reactive groups while leaving other reactive groups variable. Shown in Fig. 7
are the 12 compound libraries that showed greater than 60% kinase activity inhibition.
Asinex Screening
Kinase Glo Assays
Asinex Corporation sent us over 1,000 individual small molecular compounds
synthesized from natural compounds. Screening these compounds, we found three individual
compounds that show greater than 60% kinase activity inhibition: compound 4-H08, compound
6-E06, and compound 7-A06 (Fig. 8). We also conducted a dose response test on these potential
hits using the Kinase Glo Assay. By using concentrations of 10μM, 5μM, 1μM, 500nm, and
100nm, we were able to determine the IC50 of these compounds by plotting a logarithmic best
16

line of fit to the graph. We used the generated logarithmic equation to determine at which
concentration 50% of kinase activity was inhibited (IC50). Compound 4-H08 had an IC50 of
3.46uM (Fig. 9), compound 6-E06 had an IC50 of 2.06μM (Fig. 10), and compound 7-A06 had an
IC50 of 2.94μM (Fig. 11).
MTS Assays
Potential hits were then subjected to the MTS cell viability assay, where it was shown
that even at the 1μM range, compounds showed significant inhibition of cell viability (Fig. 12).
After, the LD50 was determined for each compound (Fig. 13-15) by plotting an exponential best
line of fit to the generated graph and calculated at what concentration 50% of cells had died
using our Live control as 100% viability. Compound 4-H08 had an LD50 of 9.99μM (Fig. 13),
compound 6-E06 had an LD50 of 9.66μM (Fig. 14), and compound 7-A06 had an LD50 of
10.95μM (Fig. 15).
TPI Compound Libraries – Identification of Potential Novel Targets
Cell-Reporter Assays
TPI compound libraries 2057 and 2165 were subjected to the cell-reporter assay in which
they showed moderate glucocorticoid receptor signaling inhibition (Fig. 16). Other compound
libraries that were not shown to have Aur-A activity inhibition, but still showed greater than 60%
inhibition in key cell receptor signaling pathways were noted (Fig. 17). Key receptor pathways
that were noted were glucocorticoid, progesterone, and androgen receptors.
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Figure 3) Kinase Glo - TPI - 10 μg/mL – Luminescence (a). Does not show any significant
kinase activity inhibition

Figure 4) Kinase Glo - TPI - 10 μg/mL - Luminescence (b). Shows compound libraries 2057
and 2165 (red) with significant kinase inhibition
18

Figure 5) Kinase Glo - TPI - 10 μg/mL - Percent ATP Usage. Shows compound libraries
2057 and 2165 (red) with significantly less ATP Usage
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Figure 6) Kinase Glo - TPI - 10 μM g/mL - Percent Kinase Activity Inhibition. Shows
compound libraries 2057 and 2165 (red) significantly inhibited Aur-A activity by at least
60%

Figure 7) TPI Secondary Positional Scanning - 10ug/mL - Shows the 12 compound libraries
within compound library 2057 that showed greater than 60% Aur-A activity inhibition
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Figure 8) Asinex Kinase Glo - 10 μM - shows the 3 compounds from Asinex that showed
greater than 660% Aur-A activity inhibition at 10uM

Figure 9) 4-H08 Dose Response Curve. Shows the IC50 of this compound was determined
to be 549nM through the Kinase Glo Assay
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Figure 10) 6-E06 Dose Response Curve. Shows the IC50 of this compound was determined
to be 1.76μM through the Kinase Glo Assay

Figure 11) 7-A06 Dose Response Curve. Shows the IC50 of this compound was determined
to be 639nM through the Kinase Glo Assay
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Figure 12) Asinex MTS Cell Viability - Shows the 3 Asinex potential hits in the MTS Assay.
At 10u μM concentrations all three compounds showed significant inhibition compared to
the DMF control

Figure 13) 4-H08 MTS LD50 Curve. Shows the best fit line for cell cytoxicity by the Asinex
compound 4-H08 as determined by the MTS assay. LD50 was determined to be 9.99μM.

23

Figure 14) 6-E06 MTS LD50 Curve. Shows the best fit line for cell cytotoxicity by the
Asinex compound 6-E06 as determined by the MTS assay. LD50 was determined to be
9.66μM

Figure 15) 7-A06 MTS LD50 Curve. Shows the best fit line for cell cytotoxicity by the
Asinex compound 7-A06 as determined by the MTS assay. LD50 was determined to be
10.95μM
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Figure 16) Using the TPI compound libraries that were potential hits in a cell-reporter
assay to determine which receptor signaling pathway they affected the most. Treatments
were completed at 10μg/mL.

Figure 17) Using TPI compound libraries to identify potential new targets for antiproliferative cancer agents. Compound libraries shown are libraries that exhibited at least
60% inhibition of less than three receptor-signaling pathways.
25

Compound Library

Name

1324
(MW > 207Da)

Dihydroimidazolylmethyldiketopiperazine

Structure

O

H
N

O
N

N

1952
(MW > 239Da)

Pyrrolidine
pentamine

R2

N

R3
NH2

R1

H
N

N

R1

R2
NH
R3

NH
R4

2048
(MW > 188.065Da)

Cyclic guanidine
linked sulfonamide

NH

HN

R2
N

R1

2057
(MW > 237.065Da)

H
N

Pyrrolidine thiazole
piperazine

N

N
N

S
R1

2165
(MW > 305.065Da)

O
S
R3
N
H O

O
R2

R1

Acylated piperazine
linked thiazole

H2N

O
R2

N
O
N

S

O
N

N

R2

Table 2) Shows the name and molecular structure of the TPI compound libraries that were
shown to be potential hits. R-groups denote a variable reactive group on the molecular
backbone.
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Compound

Name

Structure

MLN 8237
(MW = 518.92Da)
Log P = 5

Benzoic acid, 4-[[9-chloro7-(2-fluoro-6methoxyphenyl)-5Hpyrimido[5,4d][2]benzazepin-2yl]amino]-2-methoxy-

4-H08
(MW = 424.507Da)
Log P = 0

1-[2-(2-{3-[4-(2aminopyrimidin-5-yl)-6methylpyridin-2yl]pyrrolidin-1-yl}-2-ox

H2N
N
N
O
O

N

N
O

N
H3C

6-E06
(MW = 386.819Da)
Log P = 3

N-{7-[(3-chloro-2fluorophenyl)carbonyl]5H,6H,7H,8H-pyrido[3,4d]pyrimidin-4-yl

O
N

F
Cl

N

N
N
H3C
N N

7-A06
(MW = 280.335Da)
Log P = 1.3

4,6-dimethyl-2-(3-{1Hpyrazolo[3,4-b]pyridin-3yl}azetidin-1yl)pyrimidine

H3C
N
N

N
N
H3C

N N

Table 3) Shows the name and chemical structure of MLN 8237, a known Aur-A inhibitor
and the Asinex compounds shown to be effective at inhibiting Aur-A activity and PC-3 cell
viability
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Discussion
In this study we sought to identify any potential anti-proliferative agents that inhibited the
mitotic process of metastatic PCa by targeting the serine-threonine mitotic kinase Aur-A.
Extensive analysis on Aur-A activity in cohesion with tens of thousands of compounds was
completed, and a small number of compounds/compound libraries were shown to be effective.
Lipinski’s Rule of 5
Lipinski’s Rule of 5 (RO5) is a common method to identify compounds that have
potential to become orally active drugs. The RO5 identifies four physiochemical properties and
defines the allowed parameters of these properties “associated with over 90% of orally active
drugs that have achieved Phase II clinical status” (Lipinski, 2001). The criteria are as follows
1. No more than 5 hydrogen bond donors
2. No more than 10 hydrogen bond acceptors
3. A molecular mass of less than 500 Daltons
4. An octanol-water partition coefficient log P not greater than 5
All compounds and libraries that were identified as “potential hits” in this study passed
the RO5 criteria. However, it is important to note that the RO5 does not guarantee a compound
is indeed drug-like nor does it analyze any of the compounds’ specific chemical structures found
in drugs or non-drugs. (Lipinski, 2001).
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TPI Compound Libraries
. It’s important to note that the TPI compound libraries seemed to not be particularly
stable compounds. During our experiments, if the compound libraries were subjected to more
than four freeze-thaw cycles, they would lose any noticeable inhibitory effect on Aur-A kinase.
This could be due to the vast majority of individual compounds per library; degradation of some
compounds could promote the degradation of other compounds as well. Unfortunately this
subsequently limited our ability to test these compounds effectively.
Regardless, TPI compound library 2057 and 2165 had shown to be quite effective Aur-A
activity inhibitors, inhibiting Aur-A’s ATP usage by nearly 67% and 64%, respectively at a
concentration of 10μg/mL. Since both compounds contain a thiazole-piperazine molecular
backbone (Table 2), it’s coherent with our data suggesting that they perform similar roles in
inhibiting Aur-A activity and receptor-signaling. In the cell-reporter assay, we found the
compound library inhibited the glucocorticoid receptor (GR) signaling pathway by 37.2% and
23.4% respectively, which suggest they have GR antagonistic activity. This is vital to note
because while PCa cells normally overexpress androgen receptors (AR), GR and AR share many
transcriptional targets including the anti-apoptotic genes for serum and glucocorticoid-regulated
kinase 1 (SGK1) and MAP kinase phosphatase I (MKP1). In fact, because it has been previously
shown that GR activity contributes to androgen-targeted therapy resistance, GR antagonists have
the potential to delay resistant tumor formation (Isikbay et al., 2014). Thus, there is hope that
these compound libraries could potentially have dual functions in inhibiting the mitotic kinase
Aur-A as well as delaying the relapse of more resistant PCa.
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TPI compounds 1324, 1952 and 2048 each showed at least 60% inhibition in less than 3
receptor signaling pathways in the cell-reporter assay. In fact, multiple libraries showed
inhibition of only one pathway: 1324 inhibited only the Liver X receptor pathway; 2048 only
affected the androgen receptor pathway; and libraries 2057 and 2165 only affected the
glucocorticoid receptor pathway. This is important to note because if all receptor-signaling
pathways were down-regulated, that means that the compound library would have a cytotoxic
effect on many if not all cells in the body rather than just metastatic cancerous cells. We screened
these compounds with the notion of identifying potential novel anti-cancerous agents that could
target more aggressive cancers, which have been shown to express multiple hormone receptors
such as progesterone, androgen, and glucocorticoid receptors. Antagonistic effects. However,
none of these compounds showed any significant Aur-A activity inhibition, and are therefore, not
main focuses of this study.
Asinex Compounds
Unlike the TPI compound libraries, the Asinex compounds were particularly more stable
and potent in our studies; more than 10 freeze-thaw cycles yielded no change on the compounds’
effect on Aur-A activity inhibition and cell viability. It’s also important to note that in the MTS
cell viability assay, these three compounds were the only out of over 1,000 compounds to show
any cytotoxicity against PC-3 cells.
Compound 4-H08 (4H) showed extreme inhibition of Aur-A kinase activity even at 1μM
where it inhibited ATP usage by 78.7%. At 10μM concentration, 4H seemed to inhibit 100% of
Aur-A kinase activity. A dose response curve was made, and the IC50 was determined to be
594nM (Fig. 9). In the MTS cell viability assay, 4H also showed great cytotoxic effects against
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PC-3 cells, showing significant inhibition at 10μM concentration. An LD50 curve was made and
it was determined that 50% of cells died at 9.99μM (Fig 13).
Compound 6-E06 (6E) showed good inhibition of Aur-A kinase activity at 10μM,
inhibiting ATP usage by 81.8%. A dose response curve was made, and the IC50 was determined
to be 1.76μM (Fig. 10). In the MTS cell viability assay, despite being a weaker Aur-A inhibitor
than 4H, it showed similar cytotoxic effects against PC-3 cells at the micromolar range. Its LD50
was determined to be 9.66μM (Fig 14).
Compound 7-A06 (7A) showed good inhibition of Aur-A kinase activity at 10μM,
inhibiting ATP usage by nearly 100%. A dose response curve was made, and the IC50 was
determined to be 639nM. In the MTS cell viability assay, it showed similar cytotoxic effects
against PC-3 cells at the micromolar range. Its LD50 was determined to be 10.65μM.
These compounds’ similar effect against Aur-A activity and PC-3 viability could be due
to the fact that they all share a pyrimidine group. It’s important to note that MLN 8237, a known
Aur-A inhibitor, also carries a pyrimidine group. Whether or not this similarity in molecular
structure is truly the reason for their similar effects is unclear and needs to be tested further.
Conclusions and Future Study
In conclusion, we identified two potential compound libraries from TPI that showed
significant inhibition of Aur-A activity and cell-receptor signaling. Further manipulation of
these compound libraries by TPI will grant us the ability to test individual compounds with the
next round of drug screening, called deconvolution screening. At that point, we may again
identify individual compounds that inhibit kinase activity by at least 60% and then test it using
the MTS cell viability assay and cell-reporter assays. For Asinex compounds, we identified 3
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out of 1,104 compounds that showed extremely strong inhibition of Aur-A activity as well as
strong cytotoxic effects on PC-3 cells. In the future, we would like to further test these
compounds with the cell-reporter assay to determine which receptor-signaling pathway it affects
the most. Moreover, we would like to see their cytotoxic effects on other cell lines to see if these
drugs are more specific to PCa cells rather than benign human cells altogether. Ultimately we
want to modulate all of these compounds to the point where we can see significant effect on AurA inhibition and PC-3 specific cytotoxicity at the nanomolar range.
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